EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML

Keith W Pratz iD, Mohamad Cherry, Jessica K Altman iD, Brenda W Cooper iD, Nikolai A Podoltsev iD, Jose Carlos Cruz, Tara L Lin, Gary J Schiller, Joseph G Jurcic, Adam Asch, Ruishan Wu, Jason E Hill iD und 6 weitere

Journal of Clinical Oncology · 10.09.2023 · 41 (26) · 4236-4246

DOI: 10.1200/jco.22.02721 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.09.2023. Verfasst von Keith W Pratz und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA. Hauptthemen laut MEDLINE: Consolidation Chemotherapy, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Gilteritinib is a type 1 FLT3 inhibitor active as monotherapy for relapsed or refractory FLT3-mutated AML. We investigated the safety, tolerability, and efficacy of gilteritinib incorporated into intensive induction and consolidation chemotherapy, and as maintenance therapy for adult patients with newly diagnosed, non–favorable-risk AML. METHODS In this phase IB study (2215-CL-0103; ClinicalTrials.gov identifier: NCT02236013 ), 103 participants were screened and 80 were allocated to treatment. The study was divided into four parts: dose escalation, dose expansion, investigation of alternate anthracycline and gilteritinib schedule, and continuous gilteritinib during consolidation. RESULTS After dose escalation, 120 mg gilteritinib once daily was chosen for further study. There were 58 participants evaluable for response at this dose, 36 of whom harbored FLT3 mutations. For participants with FLT3-mutated AML, the composite complete response (CRc) rate was 89% (83% were conventional complete responses), all achieved after a single induction cycle. The median overall survival time was 46.1 months. Gilteritinib was well-tolerated in this context although the median time to count recovery during induction was approximately 40 days. Longer time-to-count recovery was associated with higher trough levels of gilteritinib, which, in turn, were associated with azole use. The recommended regimen is gilteritinib at a dose of 120 mg once daily from days 4 to 17 or 8 to 21 of a 7 + 3 induction with either idarubicin or daunorubicin and from day 1 continuously with high-dose cytarabine consolidation. Maintenance therapy with gilteritinib was well-tolerated. CONCLUSION These results demonstrated the safety and tolerability of gilteritinib incorporated into an induction and consolidation chemotherapy regimen, and as single-agent maintenance therapy for patients with newly diagnosed FLT3-mutant AML. The data herein provide an important framework for the design of randomized trials comparing gilteritinib with other FLT3 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Consolidation ChemotherapyLeukemia, Myeloid, AcuteAdultHumansNeoplasm Recurrence, LocalIdarubicinProtein Kinase Inhibitorsfms-Like Tyrosine Kinase 3MutationAniline CompoundsPyrazines

Substanzen

IdarubicinProtein Kinase Inhibitorsfms-Like Tyrosine Kinase 3gilteritinibAniline CompoundsPyrazines

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Morristown Medical Center, Carol G. Simon Cancer Center, Morristown, NJ.
  • Department of Medicine, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.
  • University Hospitals, Cleveland Medical Center, Cleveland, OH.
  • Yale School of Medicine, New Haven, CT.
  • Methodist Hospital, San Antonio, TX.

ORCID-Profile: Keith W Pratz, Jessica K Altman, Brenda W Cooper, Nikolai A Podoltsev, Jason E Hill, Stanley C Gill, Angela J James, Alexander E Perl, Mark J Levis

Zitieren

APA

Pratz, K. W., Cherry, M., Altman, J. K., Cooper, B. W., Podoltsev, N. A., Cruz, J. C., Lin, T. L., Schiller, G. J., Jurcic, J. G., Asch, A., Wu, R., Hill, J. E., Gill, S. C., James, A. J., Rich, E. S., Hasabou, N., Perl, A. E., & Levis, M. J. (2023). Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. Journal of Clinical Oncology, 41(26), 4236-4246. https://doi.org/10.1200/jco.22.02721

Vancouver

Pratz KW, Cherry M, Altman JK, Cooper BW, Podoltsev NA, Cruz JC, et al. Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. Journal of Clinical Oncology. 2023;41(26):4236-4246. doi:10.1200/jco.22.02721

BibTeX
@article{Pratz2023,
  author = {Pratz, Keith W and Cherry, Mohamad and Altman, Jessica K and Cooper, Brenda W and Podoltsev, Nikolai A and Cruz, Jose Carlos and Lin, Tara L and Schiller, Gary J and Jurcic, Joseph G and Asch, Adam and Wu, Ruishan and Hill, Jason E and Gill, Stanley C and James, Angela J and Rich, Elizabeth Shima and Hasabou, Nahla and Perl, Alexander E and Levis, Mark J},
  title = {Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {26},
  pages = {4236--4246},
  doi = {10.1200/jco.22.02721}
}
Kostenlos starten →